RIVANNA secures $800,000 Virginia Catalyst Grant alongside matching funds to advance AI-enabled ultrasound platform for neuraxial anesthesia
CHARLOTTESVILLE, Va., Aug. 14, 2025 /PRNewswire/ — RIVANNA®, developers of world-first imaging-based medical technologies, was recently awarded grant funding valued at $800,000 from the Virginia Catalyst Program to advance the Accuro® 3S diagnostic ultrasound system. RIVANNA worked in collaboration with the University of Virginia (UVA), represented by William Manson, MD, Associate Professor of Anesthesiology and Medical Director of Perioperative Medicine, and Virginia Commonwealth University (VCU), represented by David Evans, MD, FACEP, Associate Professor of Emergency Medicine and Division Chair and Medical Director of Clinical Ultrasound, in order to develop the proposal.
Working in concert with RIVANNA leadership, including Will Mauldin, PhD, Chairman and Chief Executive Officer, Adam Dixon, PhD, Chief Technology Officer, and Paul Sheeran, PhD, Director of R&D, this project aims to address a critical need in the anesthesia field by delivering real-time needle guidance during neuraxial procedures, providing clinicians with greater precision and improved outcomes. This technology has the potential to enhance patient safety and satisfaction, while also improving provider efficiency during epidural placements. These advantages will be especially impactful for challenging cases, such as in patients with high BMI or anatomical abnormalities.
